0001213900-20-014816.txt : 20200612 0001213900-20-014816.hdr.sgml : 20200612 20200612160546 ACCESSION NUMBER: 0001213900-20-014816 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200612 FILED AS OF DATE: 20200612 DATE AS OF CHANGE: 20200612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tiziana Life Sciences plc CENTRAL INDEX KEY: 0001723069 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38723 FILM NUMBER: 20960250 BUSINESS ADDRESS: STREET 1: 3RD FLOOR, 11-12 ST. JAMES'S SQUARE CITY: LONDON, ENGLAND STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 0044(0) 207-495-2379 MAIL ADDRESS: STREET 1: 3RD FLOOR, 11-12 ST. JAMES'S SQUARE CITY: LONDON, ENGLAND STATE: X0 ZIP: SW1Y 4LB 6-K 1 ea122944-6k_tiziana.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

June 2020

 

Commission File Number: 0001723069

 

 

Tiziana Life Sciences plc
(Exact Name of Registrant as Specified in Its Charter)

 

3rd Floor,

11-12 St. James’s Square

London SW1Y 4LB

United Kingdom

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. 

Form 20-F ☒  Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K 

As previously disclosed on April 10, 2020, Tiziana Life Sciences plc (the “Company”), entered into an ATM Sales Agreement (the “Offering Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., as sales agent (“ThinkEquity”), pursuant to which the Company may offer and sell, from time to time through ThinkEquity American Depositary ADSs, each representing five (5) ordinary shares with a nominal value of £0.03 (the “ADSs”), having an aggregate offering price of up to $20 million.

The offering of ADSs pursuant to the Offering Agreement terminates upon the earliest of (a) the sale of all of the ADSs subject to the Offering Agreement, (b) the termination of the Offering Agreement by ThinkEquity or the Company, as permitted therein, or (c) June 11, 2020.

On June 9, 2020, the Company and ThinkEquity entered into an amendment to the Offering Agreement changing the date of termination of the Offering Agreement to July 31, 2020.

-2-

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  TIZIANA LIFE SCIENCES PLC
       
Dated: June 12, 2020 By: /s/ Kunwar Shailubhai  
   

Kunwar Shailubhai

Chief Executive Officer

  

 

-3-